Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

COMPLETED

European Trial of Pirfenidone in BOS, A European Multi-center Study

Lead Sponsor:

Rigshospitalet, Denmark

Conditions:

Disorder Related to Lung Transplantation

CLAD, Bronchiolitis Obliterans

Eligibility:

All Genders

18+ years

Phase:

PHASE2

PHASE3

Brief Summary

A European multi-centre, randomised, double-blind placebo-controlled trial of Pirfenidone in bronchiolitis-obliterans-syndrome grade 1-3 in lung transplant recipients. Randomized double blinded, plac...

Detailed Description

Title of the study: A European multi-centre, randomised, double-blind placebo-controlled trial of Pirfenidone in bronchiolitis-obliterans-syndrome grade 1-3 in lung transplant recipients Study design...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Patients \>18 years of age
  • Azithromycin therapy for at least 4 weeks prior to study start, with an Azithromycin dose of minimum 250 mg/day at least 3 times per week as this is considered standard therapy for bronchiolitis obliterans syndrome.
  • Double lung transplantation is required.
  • Patients must be at least 6 months after transplantation and must have documented post-transplant baseline value of FEV1 (mean of the 2 highest values measured at least 3 weeks apart according to ISHLT criteria).
  • Patients must have BOS grade 1 to BOS grade 3.
  • Patients must have documented progressive disease as demonstrated by all of the following criteria:
  • Patients must have at least 3 FEV1-measurements in the last 6 months, each at least 3 weeks apart
  • a total decline of at least 200ml in FEV1 i
  • a decline of at least 50 ml in the last two measurements
  • Exclusion Criteria
  • Patients with lung redo transplantation, combined transplantation (including heart and lung transplantation) or single lung recipients.
  • Patients with any severe comorbidity complicating BOS which might determine the prognosis and functional level of the patient (e.g. invasive aspergillosis, active malignant disease) within the last 12 months.
  • FEV1 decline related to other non BOS causes (eg pneumothorax, bronchial stenosis, effusion, etc.)
  • Patients who have developed BOS grade 3.
  • Patients who on Thorax CT at entry demonstrate new significant findings which are not compatible with BOS like interstitial fibrosis, consolidation, appearances suggesting Restrictive Allograft Syndrome (RAS) and acute pulmonary infection as cause of decline in lung function.
  • Documented acute perivascular rejection higher than grade A1 or findings compatible with antibody mediated rejection
  • Pregnancy or lactation (women of childbearing capacity are required to have a negative serum pregnancy test before treatment and must agree to maintain highly effective contraception by practicing abstinence or by using at least two methods of birth control from the date of consent through the end of the study).
  • Renal insufficiency (Creatinine clearance \<30 ml/min calculated by the CKD-Epi formula.
  • Any of the following liver test criteria above the specified limit:
  • Total bilirubin above the upper limit of the normal range (ULN), except in patients with predominantly unconjugated hyperbilirubinemia (e.g., Gilbert's syndrome)
  • Aspartate or alanine aminotransferase (AST or ALT) \>3 × ULN
  • Known allergy or hypersensitivity to Pirfenidone
  • Ongoing use or expected use of any of the following therapies:
  • Strong inhibitors of CYP1A2 (e.g. fluvoxamine or enoxacin)
  • Moderate inhibitors of CYP1A2 (e.g. mexiletine, thiabendazole, or phenylpropanolamine \[Note: ciprofloxacin will be allowed only at doses ≤500 mg BID\])
  • Previous treatment with Pirfenidone after transplantation
  • Patients who have resumed smoking after transplantation

Exclusion

    Key Trial Info

    Start Date :

    May 1 2015

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    December 1 2019

    Estimated Enrollment :

    90 Patients enrolled

    Trial Details

    Trial ID

    NCT02262299

    Start Date

    May 1 2015

    End Date

    December 1 2019

    Last Update

    January 18 2020

    Active Locations (9)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 3 (9 locations)

    1

    University Hospital Gasthuisberg, Katholike Universiteit Leuven

    Leuven, Belgium, 300

    2

    Rigshospitalet, Copenhagen University Hospital

    Copenhagen, Denmark, 2100

    3

    University Hospital Essen, Department of Pneumonology

    Essen, Germany, 45239

    4

    Medizinische Hochschule Hannover, Klinik für Pneumonologie

    Hanover, Germany, 30625